The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

HHS Secretary Robert F. Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman's risk for as many as 14 cancers associated ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China. Phase 2 data suggest ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to soar 35% over the next 12 months.